Skip to main content
  • Saved

Commented on 's Post

Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report - PubMed

Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/33842645/

Immunotherapy has been proved to be a promising candidate for advanced non-small cell lung cancer (NSCLC). Despite MET mutations are regarded as an independent factor of programmed death ligand 1 (PD-L1) high expression, the efficacy of immune checkpoint inhibitors (ICIs) across NSCLC harboring Mese ...

  • 2 weeks 1 day
    Key Points
    • Case study indicating that NSCLC with METex14 had a significant response to anti-PD-1 therapy. Even though targeted therapy has become the mainstay regimen of NSCLC with METex14, treatment-resistant genes will ultimately appear.
    • The authors noted that although targeted therapy is the principal treatment of NSCLC with METex14, therapeutic resistance will crop up. Immunotherapy could hold promise for treating advanced NSCLC patients with METex14 alterations. This approach may be particularly effective in those harboring MET-TKI resistant mutations (e.g., D1228N/E/G/H, Y1230C/D/S/H/N). Consequently, the authors recommended further prospective trials.
    • Importantly, the authors wrote that “the interpretation of immunotherapy resistance could be tricky in some circumstances. Previous studies revealed that the organ-specific niche, e.g., bone and liver, might be resistant to the development of Th1 effector CD4 T cells or CD8 cytotoxic T cells, which might be why PD-1 antibody plus VEGFR-TKI fail to control bone metastases.”
    • The authors are the first to report that salvage CTLA-4 antibody and PD-1 antibody can be effective in the setting of resistant anti-PD-1 with NSCLC. To overcome resistance, the authors recommended combining anti-PD-1 therapy with other immunomodulators or immune agonists, such as CTLA-4 antibody, rather than discontinue use.